How Goldman Currently Rates Horizon Pharma (NASDAQ:HZNP)
In an analyst research report sent to investors on Thursday morning, stock analysts at Goldman initiated coverage on Horizon Pharma (NASDAQ:HZNP) shares. The brokerage issued a key Buy rating for HZNP stock.
From a total of 9 analysts covering Horizon Pharma (NASDAQ:HZNP) stock, 7 rate it a ”Buy”, 0 a “Sell”, and 1 a ”Hold”. This means that 88% of the ratings are positive. The highest target price is $46 while the lowest target price is $23. The mean of all analyst targets is $38.67 with a 55.51% above today’s ($21.22) stock price. Horizon Pharma was the topic of 7 analyst reports since September 9, 2015 according to the firm StockzIntelligence Inc. Mizuho maintained shares on December 14 with “Buy” rating. Jefferies reinitiated HZNP stock in a recent report from November 23 with “Buy” rating. Finally, JMP Securities reinitiated the stock with “Mkt Outperform” rating in a report issued on a September 9.
Approximately 887,320 shares of stock traded hands. Horizon Pharma PLC (NASDAQ:HZNP) has declined 25.53% since May 14, 2015 and is downtrending. It has underperformed by 23.26% the S&P500.
The overall sentiment of institutions has decreased to 1.03 in Q2 2015. Its down 0.48, from 1.51 in 2015Q2. The ratio worsened, as 55 institutions have sold all the shares of Horizon Pharma PLC that they owned while 71 funds have taken shares off the table. 60 funds have purchased shares for the first time while 70 added to their positions. These institutions now hold 142.56 million shares or 14.58% more than the 124.42 million shares they owned in 2015Q2.
The Fund Broadfin Capital Llc currently is holding shares equating to 7.37% of its total portfolio in Horizon Pharma PLC representing a total of 6.67 million shares. Another fund,Deerfield Management Co, is holding a total of 8.08 million shares equating to 6.2% of their holdings. Additionally, Jw Asset Management Llc has a 773,899 share stake in Horizon Pharma PLC which represents 5.56% of their total portfolio. The Fund, Turner Investments L.P., based out of Pennsylvania, has also built up a stake in the stock, which represents a total of 2.57% of their total portfolio. Finally Marble Arch Investments Lp, a fund which is based in the state of New York reported a total holdings of 1.62 million shares.
Insider activity is a very important aspect to track on any stock. Going back to March 11, 2015, shareholders of Horizon Pharma PLC have witnessed 0 insider purchases, and a total of 2 sales equating to a net activity of approximately $1.20 million . Sherman Jeffrey W sold 7,750 shares worth approximately $246,295. Himawan Jeff sold 554,564 shares worth approximately $12.44 million.
Horizon Pharma plc, formerly Vidara Therapeutics International Public Limited Company, is a specialty biopharmaceutical firm focused on identifying, developing, acquiring or in-licensing and commercializing differentiated products that address unmet medical needs. The company has a market cap of $3.36 billion. The Firm markets a portfolio of products in arthritis, inflammation and orphan diseases. It currently has negative earnings. The Company’s the United States marketed products are ACTIMMUNE , DUEXIS (ibuprofen/famotidine), PENNSAID (diclofenac sodium topical solution) 2% w/w (PENNSAID 2%), RAYOS (prednisone) delayed-release tablets and VIMOVO (naproxen/esomeprazole magnesium).
According to Zacks Investment Research, “Horizon Pharma plc is a specialty biopharmaceutical company focused on improving patients’ lives by identifying, developing, acquiring and commercializing differentiated products that address unmet medical needs. The company markets a portfolio of products in arthritis, inflammation and orphan diseases. The company’s U.S. marketed products are ACTIMMUNE? (interferon gamma-1b), DUEXIS? (ibuprofen/famotidine), PENNSAID? (diclofenac sodium topical solution) 2% w/w, RAYOS? (prednisone) delayed-release tablets and VIMOVO? (naproxen/esomeprazole magnesium). Horizon’s global headquarters are in Dublin, Ireland.”